# 🧬 CGT 每日情报 (Daily Brief)
> **日期**: 2026-01-27 | **更新时间**: 09:14 (北京时间)
> **监控范围**: Global (In vivo/FDA) & China (NMPA/Biotech)

---

## 🌍 全球前沿 (FDA / In vivo / MNCs)
- `[08:00]` **🏛️监管 | 信达生物宣布IBI3003（GPRC5D/BCMA/CD3三特异性抗体）获得美国FDA快速通道认定，用于治疗复发或难治性多发性骨髓瘤**
  <br><small>🇬🇧 *Innovent Announces IBI3003 (GPRC5D/BCMA/CD3 Trispecific Antibody) Receives Fast Track Designation from the U.S. FDA for Relapsed or Refractory Multiple Myeloma* [🔗Source](https://news.google.com/rss/articles/CBMiswJBVV95cUxQcHlIWk5CWVAtMjRWbk9Md3hjNFVycEZhYUxPcGRka3p1VjBLZGVMcEt3ZVpVelgxd05rcVFDQWQ2TnJzazNaSm5XM25GdVVTNWl3M2t0Tk9LUmlaMnFNWV9NOF9wVEUyN1Bzbm9JVDlKRERORnR5S2Q5Z1BKdTZuT2xSZFNYNHRGaWkyNVE0VU1uSmRVWlVoWVBQbVRKaFRRR2t3UVpoX2ZJaHdUOVpoeENMNUE5VWxOVGJBWmpBV0RzQ045NUZLa3NxZkg3S0d4WTk2bF9tZmJrM0JTSDJLdGkydWQ4UEs1UmNWS01TWTdlU0VLU3NERU9xYnhjNG40Snl5bzJ5Y1hRbkVGMDQ2QWJaQzBhNVlfbklDYi00cnlKYnN3amZWa04zdm41a2xyZmRZ?oc=5)</small>
- `[23:16]` **打破障碍：2026 年顶级临床领导者如何颠覆慢性病市场**
  <br><small>🇬🇧 *Breaking Barriers: How 2026's Top Clinical Leaders Are Disrupting Chronic Disease Markets* [🔗Source](https://news.google.com/rss/articles/CBMi2wFBVV95cUxPbkFSZ1N0RmpuUWdaTjdrY1h5cGxJdGlJSUJHOGhLeDZwclNpMk9peFlBN2VJWUM4czRnbFRBekF3M3Y0alpiM0xid0thMl9oMXBYT1J2ZGtTZUExV083bHUtUGlTTGl4WDF6U25sR3VPcW1CaEVnWUh5THV3OWJSX293bGJJSThueXBjeTFZbGNITEtzRjVVeWxKbEN0MEtFLThZcjhMLWY1NURQeUxhZkRDT2JZZkh0N25sbkp4Vk5zLUd0c0JIRTdvUXhaa3FUdW1laF90b1JsbEk?oc=5)</small>
- `[22:30]` **🏛️监管 | StemCyte 宣布 FDA 批准 RegeneCyte®（HPC、脐带血）扩大使用计划，以解决长期新冠肺炎期间未得到满足的需求**
  <br><small>🇬🇧 *StemCyte Announces FDA Clearance of Expanded Access Program for RegeneCyte® (HPC, Cord Blood) to Address Unmet Need in Long COVID* [🔗Source](https://news.google.com/rss/articles/CBMijgJBVV95cUxPYjhjTUE5UlRGMjZhTWRSR01PUVpuNGh3dUJfVkgwU3VEdXV5SkgyeklIUFVzVW9ENXpvbGRsRjJsNG4xY1QxYmlZbms0cDI4SGlsLWhsRV9fNDRZQ1RtUTZ6WUl4OFhDRklUT1daSUNIUHBndHpYSUt2SU05NVpvOWRPUDZESkhRMlFsNHRrRzg3U3VPVmppRU9PRnJ6eWJYVVQ5Mk5ncy1JVDBiTERORUM1ME05QkRaNU5LRDVQc0ZxNGd0U0g5V3ppQnZQS2ZVT3d4ckoxaXk2aW8tdTI5T0xRcWV5djQ3UzBnd0NrSGlpcnhaeG9ncndNNWJYMTVBMDJRQkVJZ2U3b2E3ZFE?oc=5)</small>
- `[21:30]` **🏛️监管 | Immusoft 的 ISP-002 获得 FDA 罕见儿科疾病指定，用于治疗 II 型粘多糖贮积症**
  <br><small>🇬🇧 *Immusoft Receives FDA Rare Pediatric Disease Designation for ISP-002 to treat Mucopolysaccharidosis Type II* [🔗Source](https://news.google.com/rss/articles/CBMi9gFBVV95cUxNVWdYUElpM3dYdmlYQ0sxVTF1YW9rYVMxVnVnRDlZWE1CM2VzUHZrQVl2b3NlNlR0bkp4MGdPSjNoZlFMQzkyNHdCaGxLYnVKS2tBSUd4Q1A5N1JhNVpELVl3SzVkVjhaUlozWTM0VVNaTHJNSFRGbWtBRlhfbDR6SmtVNEFGMlpWanFndVB2Y2lEVUdDSDlxYWFsVnFqZjdCWnk5U3ZxLUFHSkIzVjlSQnJvdWhja01qci1LTTlaY3BOSVBzMlV1bXJ0SHU5NnFrWWtZck1SRENjOS1PUXFhVEpKS2dBT0V5YlZGQVR0dDhtTVhMN0E?oc=5)</small>

---

## 🇨🇳 中国动态 (NMPA / Domestic Players)
- `[17:53]` **新景智源完成逾 2 亿元 B 轮融资，加速实体肿瘤 TCR-T 疗法临床攻坚** [🔗阅读原文](https://news.google.com/rss/articles/CBMifkFVX3lxTE42RmU1TWxWd0lBUkowanlLblh0MnBiNHFldkJkdHVFbDYzNEVnVTFGaE4wVGlVUXJxQkhac284anMyLTM2RG9YQlFPMHlEdF9ZRGwtV2dZVDlmWXJtanl0X2RsbHhfT29rby1ta2toRXphSHlJakx0UXVQSnFtQQ?oc=5)
- `[12:13]` **晚期胃癌治疗新希望：IMC002 CAR-T疗法突破性进展，66.7%缓解率与卓越安全性解析** [🔗阅读原文](https://news.google.com/rss/articles/CBMiRkFVX3lxTE15dWFORkdENjU3a1JrQk5nM0dlMnNHbnRQR1QtRVpWV0tCTmxuUW9NZk52d0dIODVtYVNZMWFrekVodWpwSWc?oc=5)
- `[10:44]` **新景智源完成逾2亿元B轮融资，加速实体肿瘤TCR-T细胞疗法药物临床开发｜BV Family** [🔗阅读原文](https://news.google.com/rss/articles/CBMifkFVX3lxTE95alpucm5MTUw4dmRsZ3R3T3NYNHlFSG5KclRqYTRQYUpjUHdYQ0N3NjUzUnlyR1I4M0t4VEM1LUNEdUdsa3dqWVF1NWFRX04tUURqaU9IN3g2eXlKYU9uaEhWcll4VnFMVDVlTlZhdklYaXRLMlRiUWRJUHpXZw?oc=5)
- `[10:28]` **德联News | 新景智源完成逾2亿元B轮融资，加速实体肿瘤TCR-T细胞疗法药物临床开发** [🔗阅读原文](https://news.google.com/rss/articles/CBMifkFVX3lxTFBPWWpJRnVOWWRUbktKRDRVLUtUUnZLaFBRdzJnaThOR3JvUU9RSDFjYkg2WV9rM0FVZlNMY0JTUFVPUVVhQ0dqNXJwOE10TnozTDE0dUZaOWZTMFlXbS1nVmVaeWtjZUlrbzRuQ2VyVWNUN1FMMnZIT2tZVENpUQ?oc=5)
